Research programme: erythropoietin mimetics - AplaGenAlternative Names: AG-EM-0040; AGE-49C; AGE-53C; Research programme: EPO mimetics - AplaGen
Latest Information Update: 30 Jan 2007
At a glance
- Originator AplaGen
- Mechanism of Action Erythropoietin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Anaemia
Most Recent Events
- 30 Jan 2007 AG-EM-0040 is still in preclinical trials for anaemia in Germany
- 30 Nov 2005 Preclinical trials in Anaemia in Germany (unspecified route)
- 30 Nov 2005 This programme is available for licensing (http://www.aplagen.com)